EyePoint, Inc. (EYPT) · Aug 17, 2026 · Other events
Below the bar — Primary endpoint missed in full dataset; ad hoc non-inferiority p=0.0096
DURAVYU delivered impressive durability and treatment-burden data, but missed LUGANO’s primary endpoint in the full dataset.
The pivotal success bar was not cleared. LUGANO’s primary endpoint—non-inferiority in vision change versus on-label aflibercept—was not achieved in the full dataset, which is the result that matters most for regulatory credibility. 〔0〕
The failure appears concentrated in an unusual imbalance, but the rescue analysis is post hoc. Nine of 211 DURAVYU patients experienced unrelated vision loss of at least 15 letters, while none did in the control arm; excluding that 4% cohort produced nominal non-inferiority. That makes the result potentially explainable, but investors and regulators will still treat the full-dataset miss as a material qualification rather than a clean win. 〔1〕
The durability profile is genuinely strong and preserves the commercial thesis. DURAVYU cut treatment burden by 42%, equivalent to two fewer injections on average through Week 56, while 54% of patients remained supplement-free and 79% needed zero or one supplemental injection. Those outcomes support the six-month dosing proposition, but they do not fully offset missing the principal vision endpoint. 〔2〕
The program now depends heavily on replication in LUCIA. Management still expects the second identical Phase 3 trial to report in Q4 2026 and potentially supports an NDA filing in the first half of 2027. The next trial must show that the LUGANO result was an isolated statistical imbalance—not a sign that the efficacy margin is less robust than expected. 〔3〕
LUCIA topline data, Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!